Inflammatory markers for predicting responses to nivolumab in patients with metastatic renal cell carcinoma.

Abbreviations & Acronyms anova analysis of variance CR complete response CT computed tomography ICI immune checkpoint inhibitor KPS Karnofsky Performance Status LMR lymphocyte-to-monocyte ratio mRCC metastatic renal cell carcinoma NLR neutrophil-to-lymphocyte ratio ORR objective response rate OS overall survival PD progressive disease PFS progression-free survival PLR platelet-to-lymphocyte ratio PR partial response RECIST Response Evaluation Criteria in Solid Tumors ROC receiver operating characteristic SD stable disease The therapeutic strategy for mRCC has expanded in recent years. Despite these limitations, the NLR is a readily available biomarker that provides additional information to predict the nivolumab response and helps in the consideration of sequence therapy in mRCC patients. [Extracted from the article]